Previous studies showed that AIM2 regulates CRC cell viability via AKT pathway [15–17] and an activated AKT/mTOR pathway promotes Gli1 activity in a SMO-independent manner [22]. This evidence concerns the gene AIM2 and colorectal carcinoma.